Remove 2026 Remove Clinical Research Remove Research Remove Therapies
article thumbnail

Article FDA Thank You The FDA rejected a psychedelic sponsor’s bid for approval. Here are six industry takeaways

Agency IQ

The road to research on psychedelic products is paved with obstacles. This means that research programs are subject to additional oversight from U.S. FDA released a draft guidance in June 2023 attempting to address many of these unique aspects of clinical research on psychedelic substances.

FDA 40
article thumbnail

Scaling up: The need for human cells to give better access to cell therapies

Drug Discovery World

Reece Armstrong speaks to Kathryn Golden , SVP Technical Operations and Manufacturing, bit.bio, about novel technologies, and methods to manufacture human cells for therapies so more patients can access these treatments. Cell therapies have emerged as transformative and potentially curative treatments across a range of disease areas.

Therapies 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

From cradle to grave: Novo Nordisk Foundation and cardiometabolic diseases 

Drug Discovery World

Together, this research aims to generate evidence for advising and guiding future parents before and during pregnancy. He thinks that the amount of money awarded in total is unique for research in this very specific field and that the research projects complement each other and the international research in this field.

Disease 162
article thumbnail

Sequana Medical to present at Jefferies 2020 Virtual London Healthcare Conference

The Pharma Data

and EU5 by 2026. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com. The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.

article thumbnail

Sequana Medical Announces January 2021 Investor Conference Schedule

The Pharma Data

and EU5 by 2026. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com. The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.

article thumbnail

Sequana Medical Appoints Two Additional Experts as Heart Failure Scientific Advisors

The Pharma Data

Pre-clinical and clinical proof-of-concept data from a first-in-human single dose DSR study demonstrated that single dose DSR therapy was safe and well-tolerated and the positive results were published in the high impact peer-reviewed cardiovascular journal, Circulation. and EU5 by 2026. Udelson James E.

article thumbnail

Advances in neuroscience drug discovery

Drug Discovery World

Recent advances in biomarkers, research into the central nervous system and breakthroughs in human iPSC cell models, have bolstered neuroscience drug discovery research. ARUK 3 adds that while the UK government increased funding in dementia research from ÂŁ28.2m years it takes to complete an entire cancer clinical trial.

Drugs 147